NCT04263363View on ClinicalTrials.gov

Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications

PHASE4CompletedINTERVENTIONAL
Enrollment

12,248

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2025

Conditions
Respiratory ComplicationObstructive Sleep Apnea
Interventions
DRUG

Sugammadex 100 MG/ML [Bridion]

Sugammadex administered to patients within the clinical best practice pathway.

Trial Locations (1)

90095

Ronald Reagan UCLA Medical Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, Los Angeles

OTHER